Sangamo Therapeutics Announces Departure of Main Fiscal Officer Sung Lee

1 min read

4 years ago FeliciaF.Rose

Sangamo Therapeutics Announces Departure of Chief Economical Officer Sung Lee

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine firm, introduced these days that Main Monetary Officer Sung Lee is leaving the Organization to go after a new option overseas. Mr. Lee’s very last working day of work will be February 1, 2021.

“Sung has contributed appreciably to Sangamo’s evolution, assisting us create a solid income place to advance proprietary medicines for patients in need to have as we commence a year with various opportunity catalysts,” claimed Sandy Macrae, Chief Government Officer of Sangamo. “I have deep appreciation for the integrity and leadership Sung brought to Sangamo. The management group and board of directors at Sangamo sign up for me in wishing him the very best as we initiate our search for a new CFO.”

“It has been a privilege to operate with Sandy and the Sangamo crew to advance the impressive industry of genomic drugs, and I imagine the organization is perfectly positioned to execute on its method,” claimed Mr. Lee.

About Sangamo Therapeutics

Sangamo Therapeutics is fully commited to translating floor-breaking science into genomic medications with the likely to transform patients’ lives making use of gene therapy, ex vivo gene-edited mobile therapy, and in vivo genome modifying and genome regulation. For a lot more details about Sangamo, take a look at www.sangamo.com.